Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
ViiV’s two-drug Dovato also boasted a high genetic barrier to the development of viral resistance.
Virtually, of course. So take a look around.
4% of total U.S. AIDS philanthropy directly addresses African Americans. Plus: Meet the top five funders helping BIPOC communities.
The single-tablet regimen is now approved for previously treated people with an undetectable viral load.
The novel attachment inhibitor led to viral suppression in 60% of people with extensive prior treatment.
Nine findings from ViiV Healthcare’s Latinx Listening Initiative
Cabotegravir injections given every eight weeks as PrEP are even more effective than daily Truvada.
A global study examined how outcomes improve when physicians engage their HIV-positive patients in joint decision-making.
The placebo-controlled trial compared injections of cabotegravir given every eight weeks versus daily Truvada as PrEP.
Plus: Their stigma-busting initiative gets a shout-out from POZ’s Best Celebrity Advocate 2019.
The agency has also lowered the weight threshold for film-coated tablets of the integrase inhibitor.
A clinical trial compared injectable cabotegravir given every eight weeks versus daily Truvada for HIV prevention.
Bonus: Your donations to the Broadway Cares effort Emergency Grants for Pandemic Relief will be matched by Gilead Sciences.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.